Lactiga in the Toronto Star

In the News
Written By Rik Mehta

Biotherapeutics company Lactiga has deeper pockets after an oversubscribed pre-seed financing round, raising $1.6 million in new capital. The company is hoping to use human breast-milk to create the next generation of anti-infectives, medicine that battles pathogens and inhibits or kills infectious organisms.

Rik Mehta https://lactiga.com
Previous

Lactiga Gets FDA Rare Pediatric Disease Designation for CVID Therapy
Next

Lactiga Therapeutics Raises $1.6M USD in Oversubscribed Pre-Seed Round, Secures $350k in Research Grants